A bacteria-based injectable therapy shrunk tumors and completely eradicated others when tested in dogs and rats, according to a new study.
Cancer Genetics isn't making money yet. But the New Jersey developer of DNA-based cancer diagnostics closed out its 2014 second quarter with smaller losses, some strategic acquisitions and a biomarker development partnership with AstraZeneca.
Biocept recently released its 2014 second-quarter earnings as well as a corresponding update on the company's progress. Its results, which include much higher losses, highlight the molecular diagnostics player's aggressive strategy to achieve commercial success, and how far away it is from actually getting there.
Exact Sciences gained FDA premarket approval for its new, cutting-edge colorectal cancer screening test. It is also well ahead in the insurance reimbursement battle.
Biocept is bringing on a veteran GE Healthcare and Quest Diagnostics executive to guide the company's insurance reimbursement and medical contract strategy.
A U.S. research team has made progress toward creating a biomarker blood test that can detect esophageal cancer on the early side, a major need in order to combat the lethal disease.
According to researchers at the Wistar Institute in Philadelphia, mice that lack a specific regulator protein live longer than mice that have it, a finding that sheds light on how metabolic networks might play a role in cancer treatment, aging and obesity.
OncoCyte is vastly expanding testing of its urine-based bladder cancer diagnostic with the launch of a multisite clinical trial involving up to 1,200 patient samples.
California's Epic Sciences nailed down $30 million in new financing it plans to use to commercialize tests that can detect circulating tumor cells during a patient's treatment, allowing for a more personalized cancer treatment as the disease evolves.
Even as the diagnostics industry continues to pursue more sophisticated approaches to cancer testing, a group from the U.K. has come up with a simple blood test that could generate much more bang for the buck.